India Pharma Outlook Team | Friday, 10 July 2026
India's Drug Deal Reform is set to tighten the country's public drug procurement system.
The move aims to stop companies with canceled manufacturing licenses from securing government contracts. Officials believe the Drug Deal Reform will close a major regulatory gap.
It will also improve transparency in drug procurement. The proposed changes will help ensure only eligible manufacturers supply medicines to public healthcare programs.
The government found that some drug manufacturers continued receiving government orders despite losing their manufacturing licenses. This happened because procurement agencies did not receive timely updates from licensing authorities. As a result, companies with canceled licenses remained eligible during the tender process.
Officials are preparing new measures to improve coordination between regulatory bodies and procurement agencies.
The proposed changes include:
The government believes these steps will improve compliance across the pharmaceutical sector. They will also reduce the chances of unauthorized companies supplying medicines.
The issue came to light after authorities noticed that some companies allegedly failed to disclose license cancellations. Procurement agencies were unaware of the changes. This allowed those firms to continue participating in government tenders.
Also Read: The Strategic Role of Regional Corridors in Future-Ready MedTech
The planned reforms focus on strengthening drug procurement procedures. Officials want every agency involved in purchasing medicines to access updated regulatory records.
Better information sharing could reduce errors during tender evaluation. It may also improve accountability among manufacturers.
The government wants procurement decisions to reflect the latest regulatory status of every supplier. This will help protect public healthcare programs from unnecessary risks.
The move also supports efforts to improve confidence in medicines supplied through government hospitals and health schemes.
The latest proposal comes as India increases oversight of the pharmaceutical industry. Regulators have already taken steps against unapproved drug formulations and irrational fixed-dose combinations.
The current proposal adds another layer of regulatory compliance. It focuses on preventing companies with canceled licenses from entering government supply chains.
Industry experts believe stronger monitoring can improve the quality of medicines supplied through public procurement. It can also create a fair environment for manufacturers that follow regulations.
The proposed reforms are still being finalized. Once implemented, they could significantly strengthen India's public procurement system. They may also prevent regulatory loopholes from affecting future government drug purchases.
